Target intelligence / Profile preview

Pyruvate kinase isoenzyme R (human erythrocyte) (PK-R)

Target
PK-R
Molecular classification
Enzyme, Transferase, Glycolytic enzyme
01

Overview

Pyruvate kinase isoenzyme R (PK-R) is the erythrocyte-specific isoform of the enzyme pyruvate kinase, encoded by the PKLR gene. It catalyzes the final, irreversible step of glycolysis: the transfer of a phosphate group from phosphoenolpyruvate (PEP) to ADP, forming ATP and pyruvate. In mature red blood cells, which lack mitochondria, PK-R is essential for ATP generation and cell survival. PK-R operates as a homotetramer and is allosterically activated by fructose 1,6-bisphosphate; its activity is subject to regulation by other effectors such as ATP. Mutations in PKLR can cause pyruvate kinase deficiency, leading to nonspherocytic hemolytic anemia, a common hereditary red blood cell disorder. Pharmacological activators, such as mitapivat, aim to restore enzymatic function in affected patients. PK-R function and deficiency are key biomarkers in clinical settings[1][2][4][5][6].

Other names
Erythrocyte pyruvate kinaseRed blood cell pyruvate kinasePKLR (gene/protein symbol)Pyruvate kinase, liver and red blood cell
02

Mechanism of action

Allosteric activation of PK-R to enhance enzyme activity, increase ATP production, and improve erythrocyte survival

03

Biological functions

Glycolysis (final step: catalyzes phosphoenolpyruvate + ADP → pyruvate + ATP)Cellular ATP generation in erythrocytesMetabolic flux regulationMaintenance of erythrocyte integrity
04

Disease associations

Nonspherocytic hemolytic anemia (pyruvate kinase deficiency)Hereditary hemolytic anemiaOther red blood cell disorders
05

Safety considerations

Compensatory reticulocytosis and iron overload (with increased hemolysis)Jaundice and gallstone risk (with enzyme dysfunction)Challenge: risk of off-target effects due to PK isoform similarity
06

Interacting drugs

Mitapivat (an allosteric activator)

1 more in the full profile.

07

Biomarkers

Reduced pyruvate kinase activity (used for diagnosis)ATP concentration in erythrocytesGenetic mutations in PKLR gene

Beyond the preview

Go deeper on Pyruvate kinase isoenzyme R (human erythrocyte) (PK-R).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pyruvate kinase isoenzyme R (human erythrocyte) (PK-R).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call